Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
With Pfizer's danuglipron discontinued and Lilly's orforglipron in Phase 3, the oral GLP-1 race is intensifying
This work was funded by the European Regional Development Fund (FEDER), through the Competitiveness Internationalization Operational Programme (POCI), and by national funds, through the Foundation for Science and Technology (FCT), under the scope of the project POCI-01-0145-FEDER-0 31987
Structures of two remaining products were not identified (Sfair et al
Then divide your target dose (in mg) by that concentration to find the injection volume in mL
Wells Fargo (WFC) Q2 CY2026 Highlights: Net Interest Income: $12.32 billion vs analyst estimates of $12.31 billion (5.2% year-on-year growth, in line) Net Interest Margin: 2.4% vs analyst estimates of 2.4% (in line) Revenue: $22.62 billion vs analyst estimates of $21.85 billion (8.2% year-on-year growth, 3.5% beat) Efficiency Ratio: 60% vs analyst estimates of 63.2% (321.7 basis point beat) EPS (GAAP): $2.00 vs analyst estimates of $1.72 (16.4% beat) Tangible Book Value per Share: $46.13 vs analyst estimates of $45.66 (6.5% year-on-year growth, 1% beat) Market Capitalization: $268.3 billion Company Overview Founded during the California Gold Rush in 1852 to provide banking and express delivery services to miners and merchants, Wells Fargo (NYSE:WFC) is a diversified financial services company that provides banking, lending, investment, and wealth management services to individuals and businesses
US$ 22.29
US$ 22.98
US$ 28.99
US$ 28.80
US$ 28.56